

Cyclophosphamide

(Cyclophosphamide*, Endoxana*) POM

- **Client Information Leaflet: [Cyclophosphamide](#)**
- **Formulations**

Injectable: 100 mg, 200 mg, 500 mg, 1000 mg powder for reconstitution. Oral: 50 mg tablets. Available through specialist pharmacies as 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg and 20 mg capsules. **VSP**

- **Action**

Metabolites crosslink DNA resulting in inhibition of DNA synthesis, RNA transcription and replication and function.

- **Use**

- Treatment of lymphoproliferative diseases and myeloproliferative disease.
- May have a role in management of certain sarcomas and carcinomas when included in metronomic chemotherapy protocols.

Use with caution in patients with renal failure; dose reduction may be required. Cyclophosphamide is no longer recommended as an immunosuppressant drug.

- **DOSES**

See Appendix for chemotherapy protocols and conversion of bodyweight to body surface area.

- **Dogs**
 - Lymphoid neoplasia: 50 mg/m²p.o. q48h or 3–4 consecutive days/week; or 200–250 mg/m² p.o., i.v. q3wk as part of a multidrug chemotherapy protocol.
 - Metronomic chemotherapy: 10–15 mg/m²p.o. q24–48h.
 - Multiple myeloma in patients refractory to melphalan: 1 mg/kg p.o. q24h.
 - Macroglobulinaemia in patients refractory to chlorambucil: 1 mg/kg p.o. q24h.
- **Cats**
 - Lymphoid neoplasia: as for dogs, except 200–300 mg/m²in ‘high dose’ COP regimes.